Balogun, E. AMalomo, S.OAdebayo, J.OIshola, A.ASoladoye, A.OBabatunde, A.S.Akinola, O.B.2020-05-232020-05-232014Balogun, E.A., Malomo, S.O., Adebayo, J.O., Ishola, A.A., Soladoye, A.O., Kolawole, O.M., Oguntoye, O.S., Babatunde, A.S., & Akinola, O.B. (2014). In-vivo Antimalarial Activity and toxicological effects of methanolic extract of Cocos nucifera (Dwarf Red Variety) husk fibre. Journal of Integrative Medicine; 12(6):504-511.http://hdl.handle.net/123456789/4019We performed a single center retrospective analysis of 84 autologous hemopoietic stem cell transplants done for AML to characterize the pattern of hemopoietic engraftment, post-transplant cytopenia and their impact on survival outcome. Following autologous transplant and engraftment, 30 patients (35.7%) had a transient secondary decline in their plt counts, which was not associated with graft rejection, relapse or infection. The median time to onset of thrombocytopenia was 59 days post transplant, with spontaneous recovery after a median period of 41 days. A secondary decline in ANC also occurred in eight patients. Patients with secondary plt decline had a significantly earlier primary plt engraftment (median 15 days) and a trend towards earlier neutrophil engraftment compared with patients who maintained steady plt counts (median 21 days). There was a trend towards a lower incidence of secondary plt decline in patients who received BM stem cells compared with those who received PBSC. No cause was evident for the occurrence of a secondary cytopenia, and it did not adversely affect survival. We conclude that secondary cytopenia is a common and harmless occurrence after autologous transplant especially from PBSC graft. Bone Marrow Transplantation (2009) 44, 175–183; doi:10.1038/bmt.2009.1; published online 9 February 2009 Keywords: acute myeloid leukemia; autologous hemopoietic stem cell transplant; engraftment kinetics; secondary platelet decline; secondary cytopenia Introduction AML refers to a group of clonal hemopoietic stem cell disorders, which are characterized by failure of differentiation and excessive proliferation of the stem cells leading to accumulation of non-functional immature myeloblasts, both in peripheral blood and BM. Anthracycline-based chemotherapeutic regimens, which are conventionally given for induction of remission, are known to produce CR in about 60–80% of patients.1–3 However, despite the initial good response by the myeloblasts to these agents, they are usually associated with a high rate of resistance and relapse, and it has been reported that majority of AML patients who achieve CR following induction will relapse within 12–24 months, and only about 7–34% will be alive and disease free by 5 years after diagnosis.4–6 Autologous hemopoietic SCT (AHSCT) has therefore been used in AML either as a component of consolidation following the initial CR or as part of salvage therapy for patients in second remission to improve the poor prognosis associated with chemotherapy alone.7–9 AHSCT has also been used for AML patients who do not immediately have matched allogeneic donors and in elderly patients who are above 60 years of age.10 The pattern of engraftment and hemopoietic recovery followingenacute myeloid leukemia;autologous hemopoieticsecondary cytopeniastem cell transplant;engraftment kinetics;secondary platelet decline;Article